Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.51 +0.26 (+0.50%)

Delayed Quote Updated: 3:59 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

38 39 Next >

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits ↗

December 19, 2024

Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.

Via Benzinga

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

December 19, 2024

From Genentech

Via Business Wire

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗

December 18, 2024

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗

December 13, 2024

An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.

Via Benzinga

New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma

December 09, 2024

From Genentech

Via Business Wire

Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

December 08, 2024

From Genentech

Via Business Wire

The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities

December 05, 2024

EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:AMZN),(NASDAQ:MDAI),(NYSE:MDT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 05, 2024

From Genentech

Via Business Wire

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029

December 04, 2024

EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy

December 04, 2024

Las Vegas, NV – December 4, 2024 – Avant Technologies, Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on...

Via FinancialNewsMedia

Topics Artificial Intelligence

NVIDIA Invested in These 2 AI Stocks, Should You?

December 02, 2024

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

Via MarketBeat

Topics Artificial Intelligence

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? ↗

November 27, 2024

Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile.

Via Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details ↗

November 26, 2024

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Via Benzinga

Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results

November 26, 2024

From Genentech

Via Business Wire

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗

November 14, 2024

CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage...

Via Talk Markets

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024

November 05, 2024

From Genentech

Via Business Wire

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer

October 30, 2024

From Genentech

Via Business Wire

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2024

Via Benzinga

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations ↗

October 23, 2024

The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss.

Via Investor's Business Daily

Can Roche Challenge Lilly and Novo in the Weight Loss Market?

October 22, 2024

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Via MarketBeat

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

October 18, 2024

From Genentech

Via Business Wire

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗

October 15, 2024

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.